The Cost of Delay

When an innovative medicine is delayed, what immediately comes to mind? Most executives would probably answer clinical trial failure, poor efficacy, unexpected safety findings, a failed pivotal study.

But increasingly, that's not what is delaying approvals.

Today's reality is quite different.

A growing proportion of regulatory approval delays are driven not by the molecule, but by chemistry, manufacturing and controls, or CMC.

Analytical validation, manufacturing readiness, facility inspections, process validation, quality systems, data integrity, supply chain robustness, the science succeeds, the product doesn't launch.

And that's a very expensive difference.

Today, I'd like to discuss why CMC has quietly become one of the largest and most underestimated sources of enterprise risks in life sciences.

Because by the time a CMC issue becomes visible to executive leadership, much of the value has already been lost.

Historically, investors tended to associate regulatory delays with questions about efficacy or safety.

Those risks remain.

But for many modern approvals, particularly in biologics, advanced therapies, and increasingly even complex small molecules, the conversation has shifted.

Many recent complete response letters, or CRLs, have highlighted manufacturing, quality, analytical, or inspection-related deficiencies rather than fundamental concerns about clinical benefit.

Importantly, this isn't limited to one technology.

Small molecules, monoclonal antibodies, cell therapies, gene therapies, radiopharmaceuticals, complex biologics, each faces increasingly sophisticated manufacturing expectations.

This shouldn't surprise us.

Scientific innovation has accelerated dramatically.

Manufacturing complexity has accelerated with it.

Regulators are asking an increasingly reasonable question.

Can this product be manufactured consistently, reproducibly and safely at commercial scale? That's not a manufacturing question.

It's a patient safety question.